See the DrugPatentWatch profile for Delstrigo
Delstrigo (300 mg) is a fixed-dose combination medication used to treat HIV-1 infection [1]. It contains three active ingredients:
* Dolutegravir 50 mg
* Lamivudine 300 mg
* Tenofovir Disoproxil Fumarate 300 mg [1]
This combination is designed to suppress the virus by preventing its replication [1].
How does Delstrigo work to treat HIV?
Delstrigo is an integrase inhibitor that works by blocking an enzyme called integrase, which HIV needs to insert its genetic material into the host cell's DNA. It also contains two nucleoside reverse transcriptase inhibitors (NRTIs) that prevent HIV from converting its RNA into DNA [1]. By combining these mechanisms, Delstrigo effectively reduces the amount of HIV in the body [1].
When might Delstrigo's patent protection end?
Drug patent expiry dates are crucial for understanding when generic versions might become available. Information on specific patent expiry dates for Delstrigo, or its individual components, can be found through resources like DrugPatentWatch.com [2]. These dates are subject to change due to various legal and regulatory factors [2].
Who makes Delstrigo and what are its alternatives?
Delstrigo is manufactured by ViiV Healthcare [1]. Several other fixed-dose combination antiretroviral therapies are available for HIV treatment, offering patients and healthcare providers a range of options. These alternatives may differ in their active ingredients, side effect profiles, and dosing schedules [3].
What clinical data supports Delstrigo's effectiveness?
Clinical trials have demonstrated Delstrigo's efficacy in suppressing viral load and maintaining or improving CD4 cell counts in individuals with HIV-1 infection [1]. These studies compare its performance against other treatment regimens [1].
What are the potential side effects of Delstrigo?
Common side effects associated with Delstrigo include nausea, diarrhea, headache, insomnia, and dizziness [1]. More serious, though less common, side effects can occur and may include hypersensitivity reactions, liver problems, and kidney issues [1]. Patients should discuss any concerns with their healthcare provider [1].
What are the risks of stopping Delstrigo treatment?
Stopping antiretroviral therapy, including Delstrigo, can lead to an increase in viral load and a decrease in CD4 cell counts, potentially allowing HIV to multiply and damage the immune system [1]. This can also increase the risk of drug resistance, making future treatments less effective [1].
What is the typical dosage and administration for Delstrigo?
The standard dosage for Delstrigo is one 300 mg tablet taken orally once daily [1]. It is important to take the medication as prescribed by a healthcare professional and to not miss doses [1].
What is the difference between Delstrigo and other HIV medications?
Delstrigo is a complete, single-tablet regimen containing three antiretroviral drugs. Other HIV treatment strategies might involve taking multiple pills daily or using different classes of drugs. The choice of medication depends on individual factors, including viral resistance, co-existing medical conditions, and potential drug interactions [3].
What are the regulatory approvals for Delstrigo?
Delstrigo has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of HIV-1 infection in adults [1].
Sources:
[1] https://www.drugpatentwatch.com/delstrigo
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/all-drugs